SecBot SecBot
6-K ·Filed Aug 4, 2026

BNTX

BioNTech SE
BEARISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001776985-26-000054
Notable filing: 6-K
Actionable Insight ▼ Bearish

The revenue miss and guidance cut are the dominant signals, COVID-19 vaccine revenue is structurally declining faster than expected. The oncology pipeline progress is real but years away from commercialization. Watch for the Q3 2026 BMS collaboration revenue recognition of €613M, which is critical to hitting the revised guidance range. The CEO transition adds execution risk during a pivotal pipeline period.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

BNTX drug pipeline →

gotistobart

● Neutral Named in this 6-K
Impact
Phase
Phase 3
Time to market
At least 2-4 years away from potential approval, assuming positive Phase 3 data leads to regulatory filing. The PRESERVE-003 Phase 3 trial is ongoing with updated OS data due Sept 2026, but no regulatory submission has been announced.
Next catalyst
None dated

What to watchThe key near-term catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. Positive data could drive BNTX shares higher, but gotistobart is one of several late-stage assets in BioNTech's broad pipeline, so the stock impact is unlikely to be binary.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$91.35
T+0 close · Aug 4, 2026 · via day close
Latest settled
−4.70%
T+60 · $87.06
Vs SPY
−5.07%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 4 $91.35entry
  2. T+1 · 3mo ago +0.91%α +1.11% · $92.18
  3. T+5 · 3mo ago +1.59%α +1.69% · $92.80
  4. T+20 · 3mo ago +11.60%α +12.84% · $101.95
  5. T+60 · 20d ago −4.70%α −5.07% · $87.06
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech reported Q2 2026 revenues of €105.6M, down 60% YoY from €260.8M, driven by declining COVID-19 vaccine demand. The company posted an IFRS net loss of €820.8M (vs. €386.6M loss in Q2 2025) and cut full-year 2026 revenue guidance to €1.6-1.9B from €2.0-2.3B. Oncology pipeline progress was highlighted with 14 ongoing pivotal trials, but the revenue miss and guidance cut dominate the near-term outlook.

Key Facts

  • Q2 2026 revenues of €105.6M, down 59.5% from €260.8M in Q2 2025
  • IFRS net loss of €820.8M in Q2 2026, more than doubling from €386.6M loss in Q2 2025
  • Full-year 2026 revenue guidance cut to €1.6-1.9B from prior €2.0-2.3B
  • Adjusted R&D expenses guidance lowered to €2.0-2.3B from €2.2-2.5B
  • Cash position remains strong at €16.6B as of June 30, 2026
  • CEO transition: Guido Oelkers appointed, to take office by February 1, 2027
  • 14 ongoing pivotal oncology trials; 6 pivotal trials initiated in H1 2026
  • XFG variant-adapted COVID-19 vaccine approved by European Commission in July 2026
  • Share repurchase program of up to $1.0B underway; $151.6M in ADSs repurchased in Q2

Financial Impact

Revenue decline of ~€155M YoY in Q2; full-year revenue guidance cut by €400M at midpoint; net loss widened by ~€434M YoY in Q2

revenuenet lossdiluted loss per shareguidance

Risk Factors

  • COVID-19 vaccine demand continues to decline faster than anticipated
  • Oncology pipeline may not generate revenue for several years, creating a revenue gap
  • CEO transition could slow strategic execution
  • R&D spending remains high at ~€2B+ annually, pressuring cash burn
  • Milestone revenue from out-licensed program delayed beyond 2026

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
79% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000054
Document: a992bntx2q2026presentati.htm0001776985-26-000054
Document: form6-kq22026earningsprear.htm0001776985-26-000054
Document: 0001776985-26-000054-index-headers.html0001776985-26-000054
Document: 0001776985-26-000054-index.html0001776985-26-000054
Document: 0001776985-26-000054.txt0001776985-26-000054

Track record

38 reports on BNTX

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.60 −1.85% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (13h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026